Stock listing
NASDAQ:PHIO Phio Pharmaceuticals Corp. Stock
Home listing (NASDAQ) of Phio Pharmaceuticals Corp.
Follow Phio Pharmaceuticals Corp. into a list and get an email when it puts out news.
Share price · NASDAQ:PHIO
$0.656 USD -0.064 (-8.9%)
Close on Nov 20, 2026
- Day range
- $0.640 – $0.731 USDNov 20, 2026
- Volume
- 145,405 sharesNov 20, 2026
- Market cap
- $7.84M USDAt the close on Nov 20, 2026 · price × 11.95M shares outstanding
- 52-week range
- $0.640 – $1.880 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $111,364 USDMedian day 86,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PHIO · Home | $0.656 USD | -0.064 (-8.9%) | 145,405 | $0.726 | $0.731 | $0.640 | $0.720 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PHIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.656 | -0.064 | -8.9% | $0.726 | $0.731 | $0.640 | 145,405 | |
| $0.720 | +0.003 | +0.4% | $0.730 | $0.767 | $0.703 | 57,935 | |
| $0.717 | -0.035 | -4.7% | $0.750 | $0.750 | $0.702 | 65,248 | |
| $0.752 | -0.019 | -2.4% | $0.767 | $0.771 | $0.720 | 76,758 | |
| $0.771 | -0.041 | -5.0% | $0.799 | $0.840 | $0.750 | 63,048 | |
| $0.812 | -0.001 | -0.2% | $0.846 | $0.860 | $0.785 | 70,919 | |
| $0.813 | -0.001 | -0.1% | $0.821 | $0.860 | $0.802 | 81,317 | |
| $0.814 | -0.026 | -3.1% | $0.800 | $0.860 | $0.790 | 55,439 | |
| $0.840 | +0.039 | +4.8% | $0.800 | $0.850 | $0.753 | 107,228 | |
| $0.801 | +0.001 | +0.2% | $0.780 | $0.830 | $0.750 | 75,614 | |
| $0.800 | -0.070 | -8.0% | $0.884 | $0.884 | $0.799 | 115,968 | |
| $0.870 | -0.033 | -3.7% | $0.885 | $0.909 | $0.862 | 59,630 | |
| $0.903 | +0.023 | +2.6% | $0.870 | $0.920 | $0.870 | 33,012 | |
| $0.880 | +0.020 | +2.3% | $0.869 | $0.900 | $0.860 | 28,820 | |
| $0.860 | -0.003 | -0.3% | $0.860 | $0.877 | $0.850 | 66,656 | |
| $0.863 | -0.054 | -5.9% | $0.880 | $0.915 | $0.863 | 25,030 | |
| $0.917 | +0.026 | +2.9% | $0.891 | $0.917 | $0.850 | 12,499 | |
| $0.891 | +0.041 | +4.8% | $0.869 | $0.920 | $0.850 | 68,029 | |
| $0.850 | -0.002 | -0.2% | $0.883 | $0.883 | $0.850 | 42,114 | |
| $0.852 | -0.021 | -2.4% | $0.859 | $0.900 | $0.851 | 30,700 | |
| $0.873 | -0.022 | -2.5% | $0.895 | $0.915 | $0.870 | 53,600 | |
| $0.895 | +0.003 | +0.3% | $0.908 | $0.920 | $0.863 | 100,300 | |
| $0.892 | +0.023 | +2.6% | $0.859 | $0.910 | $0.859 | 60,600 | |
| $0.869 | -0.002 | -0.2% | $0.870 | $0.890 | $0.851 | 90,700 | |
| $0.871 | -0.055 | -5.9% | $0.910 | $0.943 | $0.871 | 91,100 | |
| $0.926 | -0.024 | -2.5% | $0.900 | $0.980 | $0.900 | 135,800 | |
| $0.950 | +0.015 | +1.6% | $0.910 | $0.950 | $0.890 | 132,200 | |
| $0.935 | +0.013 | +1.4% | $0.960 | $0.960 | $0.920 | 69,200 | |
| $0.922 | -0.057 | -5.8% | $0.985 | $0.985 | $0.910 | 45,500 | |
| $0.979 | +0.006 | +0.6% | $0.970 | $1.000 | $0.970 | 43,200 | |
| $0.973 | -0.027 | -2.7% | $0.970 | $0.992 | $0.970 | 66,000 | |
| $1.000 | +0.006 | +0.6% | $0.994 | $1.020 | $0.970 | 92,900 | |
| $0.994 | +0.003 | +0.3% | $1.000 | $1.020 | $0.971 | 131,800 | |
| $0.991 | +0.006 | +0.6% | $1.000 | $1.120 | $0.980 | 202,600 | |
| $0.985 | -0.015 | -1.5% | $1.000 | $1.020 | $0.980 | 54,200 | |
| $1.000 | -0.030 | -2.9% | $1.050 | $1.050 | $1.000 | 50,100 | |
| $1.030 | 0.000 | 0.0% | $1.050 | $1.067 | $1.030 | 99,500 | |
| $1.030 | +0.020 | +2.0% | $1.020 | $1.050 | $1.000 | 80,600 | |
| $1.010 | 0.000 | 0.0% | $1.000 | $1.040 | $0.990 | 112,200 | |
| $1.010 | -0.010 | -1.0% | $1.030 | $1.050 | $0.987 | 238,500 | |
| $1.020 | 0.000 | 0.0% | $1.030 | $1.040 | $0.990 | 64,900 | |
| $1.020 | +0.020 | +2.0% | $1.020 | $1.030 | $1.000 | 75,200 | |
| $1.000 | -0.010 | -1.0% | $1.020 | $1.050 | $0.990 | 204,100 | |
| $1.010 | -0.020 | -1.9% | $1.040 | $1.050 | $1.000 | 78,500 | |
| $1.030 | +0.010 | +1.0% | $1.040 | $1.060 | $1.010 | 156,600 | |
| $1.020 | +0.021 | +2.1% | $1.030 | $1.040 | $0.988 | 79,500 | |
| $0.999 | -0.021 | -2.1% | $1.000 | $1.020 | $0.978 | 62,800 | |
| $1.020 | -0.010 | -1.0% | $1.040 | $1.040 | $0.990 | 114,500 | |
| $1.030 | 0.000 | 0.0% | $1.030 | $1.050 | $1.010 | 67,200 | |
| $1.030 | +0.020 | +2.0% | $1.030 | $1.050 | $1.025 | 94,400 | |
| $1.010 | -0.020 | -1.9% | $1.030 | $1.030 | $0.980 | 93,200 | |
| $1.030 | 0.000 | 0.0% | $1.035 | $1.060 | $1.030 | 138,200 | |
| $1.030 | -0.050 | -4.6% | $1.070 | $1.080 | $1.020 | 320,300 | |
| $1.080 | -0.030 | -2.7% | $1.100 | $1.125 | $1.075 | 86,600 | |
| $1.110 | -0.020 | -1.8% | $1.140 | $1.140 | $1.090 | 126,600 | |
| $1.130 | +0.030 | +2.7% | $1.070 | $1.170 | $1.066 | 240,000 | |
| $1.100 | +0.010 | +0.9% | $1.080 | $1.110 | $1.055 | 282,700 | |
| $1.090 | -0.040 | -3.5% | $1.130 | $1.130 | $1.080 | 250,200 | |
| $1.130 | +0.010 | +0.9% | $1.120 | $1.150 | $1.110 | 88,300 | |
| $1.120 | -0.080 | -6.7% | $1.210 | $1.210 | $1.100 | 242,600 | |
| $1.200 | +0.010 | +0.8% | $1.180 | $1.220 | $1.170 | 115,800 | |
| $1.190 | +0.020 | +1.7% | $1.140 | $1.220 | $1.140 | 270,145 | |
| $1.170 | -0.010 | -0.8% | $1.190 | $1.210 | $1.130 | 228,253 | |
| $1.180 | -0.030 | -2.5% | $1.240 | $1.240 | $1.170 | 138,300 | |
| $1.210 | +0.060 | +5.2% | $1.160 | $1.220 | $1.100 | 332,900 |
Splits
6 splits since 2013 · NASDAQ:PHIO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-9 | Consolidation | |
| 1-for-12 | Consolidation | |
| 1-for-55 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-30 | Consolidation |
- Ticker
- NASDAQ:PHIO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Latest news
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Nov 12, 2026
Closed $0.812 (-0.2%) on Nov 12, 2026
Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
Nov 9, 2026
Closed $0.84 (+4.8%) on Nov 9, 2026
Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
Nov 6, 2026
Closed $0.801 (+0.2%) on Nov 6, 2026
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
Nov 5, 2026
Closed $0.801 (+0.2%) on Nov 6, 2026
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Oct 19, 2026
Closed $0.869 (-0.2%) on Oct 19, 2026
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
Oct 13, 2026
Closed $0.935 (+1.4%) on Oct 13, 2026
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
Oct 6, 2026
Closed $0.994 (+0.3%) on Oct 6, 2026
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
Oct 5, 2026
Closed $0.991 (+0.6%) on Oct 5, 2026
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Sep 23, 2026
Closed $1.02 (+2.0%) on Sep 23, 2026
Phio Pharmaceuticals Corp. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 37 in the last 12 months · 189 in all · newest Nov 12, 2026 · oldest 2019
- Decks
- 9 decks · latest Jan 6, 2023
Where Phio Pharmaceuticals Corp. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PHIO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PHIO | BOATS | United States | USD |
| Munich:44R1 | Munich | Germany | EUR |
Valuation
Price/book 0.9× against a median of 1.1×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$2.77M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.24
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Phio Pharmaceuticals Corp. · NASDAQ:PHIO | US$7.84M | −US$2.77M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.24 |
| Intensity Therapeutics, Inc. · NASDAQ:INTS | US$8.19M | −US$220,086 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.30 |
| Palatin Technologies, Inc. · AMEX:PTN | US$8.16M | US$4.58M | n/a | 12.7× | n/a | 4.0× | n/a | 0.1× | 0.61 |
| Dare Bioscience, Inc. · NASDAQ:DARE | US$8.01M | −US$2.65M | n/a | −1.9× | n/a | 3.4× | −749.8% | 0.4× | 1.34 |
| Cellectar Biosciences, Inc. · NASDAQ:CLRB | US$8.00M | −US$15.05M | n/a | n/a | n/a | 0.4× | n/a | 0.1× | 1.71 |
| Immuron Limited · ASX:IMC | US$7.91M | US$1.94M | n/a | 0.4× | n/a | 1.1× | −49.8% | 0.0× | n/a |
| Vivesto AB · OMXSTO:VIVE | US$7.76M | US$6.12M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | n/a |
| Annexin Pharmaceuticals AB · OMXSTO:ANNX | US$7.59M | US$6.18M | n/a | n/a | n/a | 6.3× | n/a | 0.0× | n/a |
| Solvonis Therapeutics PLC · LSE:SVNS | US$7.57M | US$6.80M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | n/a |
| Vistagen Therapeutics, Inc. · NASDAQ:VTGN | US$7.56M | −US$11.87M | n/a | −5.0× | n/a | 0.5× | n/a | 0.0× | 1.47 |
| Noxopharm Ltd. · ASX:NOX | US$7.52M | US$10.36M | n/a | 11.0× | n/a | n/a | −312.2% | n/a | n/a |
| Median of the others | US$7.84M | US$3.26M | 0.4× | 1.1× | −312.2% | 0.0× | 1.34 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 14.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.41 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Robert Bitterman | President & Chief Executive Officer |
| Lisa Carson | Chief Financial Officer |
| Greg Young | VP Corporate Services |
| Jennifer Phillips | SVP of Regulatory & Corporate Affairs |
| John M. Viglotti | SVP Corporate Services |
| Kimberly Man | Vice President of Program Development and Strategic Planning |
Board
| Director | Role |
|---|---|
| R. Todd Plott | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +0.2% |
| Q2 2026 | Aug 13, 2026 | +0.9% |
| Q1 2026 | May 7, 2026 · After close | −6.1% |
| Q4 2025 | Mar 6, 2026 | +3.4% |
| Q3 2025 | Nov 13, 2025 · After close | −9.1% |
| Q2 2025 | Aug 14, 2025 · After close | −0.5% |
| Q1 2025 | May 15, 2025 | −1.1% |
| Q4 2024 | Mar 31, 2025 · After close | −5.4% |
| Q3 2024 | Nov 14, 2024 · After close | −0.9% |
| Q2 2024 | Aug 14, 2024 · After close | −1.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 1, 2024 · After close | +0.6% |
| Q4 2023 | Mar 20, 2024 · Before open | +8.8% |
| Q3 2023 | Nov 9, 2023 · After close | +5.9% |
| Q2 2023 | Aug 10, 2023 · After close | −1.8% |
| Q1 2023 | May 11, 2023 · After close | −10.1% |
| Q4 2022 | Mar 22, 2023 · After close | +8.2% |
| Q3 2022 | Nov 10, 2022 · After close | −11.1% |
| Q2 2022 | Aug 11, 2022 · After close | −3.6% |
| Q1 2022 | May 12, 2022 · After close | +2.3% |
| Q4 2021 | Mar 22, 2022 · After close | +4.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2023) | Investor deck | 18 slides | Jan 6, 2023 |
| RXi Pharmaceuticals — IPO Roadshow (September 2018) | IPO roadshow | 19 slides | Sep 14, 2018 |
| RXi Pharmaceuticals — Investor Presentation (March 2018) | Investor deck | 14 slides | Mar 27, 2018 |
| RXi Pharmaceuticals — 2nd Annual Oligonucleotide and Peptide Therapeutics Conference (March 2017) | Conference | 27 slides | Mar 29, 2017 |
| RXi Pharmaceuticals — 5th Annual Cancer BioPartnering & Investment Forum 2017 | Conference | 15 slides | Mar 28, 2017 |
| RXi Pharmaceuticals — Investor Presentation (November 2016) | Investor deck | 35 slides | Nov 30, 2016 |
| RXi Pharmaceuticals — 15th Annual Biotech in Europe Forum for Global Partnering and Investment Conference 2015 | Conference | 7 slides | Sep 29, 2015 |
| RXi Pharmaceuticals — 15th Annual Biotech in Europe Forum for Global Partnering and Investment Conference 2015 | Conference | 21 slides | Sep 29, 2015 |
| RXi Pharmaceuticals — Investor Presentation (March 2013) | Investor deck | 38 slides | Mar 7, 2013 |
Financings
| Raise | Date |
|---|---|
| Warrant exercise of shares of common stock on exercise of existing warrants, with new unregistered warrants Tranche closed: US$11.5M raised · US$2.05 a share · Warrants at US$2.05 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and, primarily, accelerated development activities for the next clinical phase of PH-762 for cutaneous carcinomas | Nov 13, 2025 |
| Registered direct offering of common stock with concurrent private placement warrants Closed: US$1.83M raised · US$3 a share · Warrants at US$3 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes, including the Phase 1b trial of PH-762 and development of PH-894 | Jan 21, 2025 |
| Warrant exercise of warrants issued July 12, 2024 Closed: US$2.9M raised · US$5.45 a share | Jan 21, 2025 |
| Registered direct offering of common stock with concurrent private placement warrants Announced: US$2.5M · US$3 a share · Warrants at US$3 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Jan 15, 2025 |
| Registered direct offering of common stock with concurrent private placement warrants Announced: US$3.19M · US$3 a share · Warrants at US$3 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Jan 14, 2025 |
| Registered direct offering of common stock with concurrent private placement warrants Announced: US$480,000 · US$2 a share · Warrants at US$2 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Dec 23, 2024 |
| Registered direct offering of common stock with concurrent private placement warrants Announced: about US$1.15M · US$2.635 a share · Warrants at US$2.51 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Dec 19, 2024 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 21.0K | 138.0K | 15.0K | 19.0K |
| Cost of revenue | 4.62M | 3.64M | 6.33M | 193.0K | 192.0K | 3.72M | 4.30M | 4.33M | 5.37M | 5.42M |
| Gross profit | -4.62M | -3.64M | -6.33M | -193.0K | -192.0K | -3.72M | 21.0K | 138.0K | -5.36M | -5.40M |
| Research and development | 4.62M | 3.64M | 6.33M | 7.01M | 8.89M | 3.72M | 4.30M | 4.33M | 5.37M | 5.42M |
| Selling, general and administrative | 4.60M | 3.74M | 4.29M | 4.45M | 4.63M | 5.08M | 4.71M | 3.18M | 4.01M | 3.62M |
| Operating income | -9.22M | -7.39M | -10.8M | -11.5M | -13.5M | -8.79M | -8.99M | -7.36M | -14.1M | -9.02M |
| Depreciation and amortization | 3.00K | 2.00K | 56.0K | 71.0K | 75.0K | 72.0K | 67.0K | 81.0K | 70.0K | 53.0K |
| EBITDA | -9.22M | -7.38M | -10.8M | -11.4M | -13.4M | -8.72M | -8.92M | -7.28M | -14.0M | -8.96M |
| Interest expense | 231.0K | 175.0K | 9.00K | 0 | 0 | 0 | 1.00K | 0 | ||
| Income before tax | -8.70M | -7.15M | -10.8M | -11.5M | -13.3M | -8.79M | -8.91M | -7.36M | -14.1M | -8.99M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.62M | 0 |
| Net income | -8.70M | -7.15M | -10.8M | -11.5M | -13.3M | -8.79M | -8.91M | -7.36M | -12.5M | -8.99M |
| Earnings per share, basic | -1.45 | -9.08 | -46.76 | -10.10 | -12.43 | -1.92 | -19.33 | -57.46 | -5.52 | -16.41 |
| Earnings per share, diluted | -9.08 | -46.76 | -10.10 | -12.43 | -1.92 | -19.33 | -57.46 | -5.52 | -16.41 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 21.0M | 5.38M | 8.49M | 11.8M | 24.1M | 14.2M | 6.93M | 14.9M | 3.58M | 12.9M |
| Short-term investments | 50.0K | 0 | ||||||||
| Current assets | 21.5M | 5.74M | 9.32M | 12.4M | 24.7M | 15.2M | 7.30M | 15.2M | 3.83M | 13.1M |
| Property, plant and equipment | 11.0K | 2.00K | 6.00K | 183.0K | 133.0K | 157.0K | 210.0K | 172.0K | 248.0K | 114.0K |
| Total assets | 21.5M | 5.74M | 9.36M | 12.8M | 25.2M | 15.7M | 8.04M | 15.3M | 4.10M | 13.4M |
| Accounts payable | 435.0K | 253.0K | 657.0K | 779.0K | 283.0K | 728.0K | 809.0K | 550.0K | 511.0K | 917.0K |
| Current liabilities | 435.0K | 1.01M | 1.63M | 1.94M | 3.07M | 2.20M | 1.88M | 1.74M | 2.27M | 2.54M |
| Long-term debt | 0 | 231.0K | 0 | |||||||
| Total debt | 35.0K | 170.0K | 0 | 231.0K | 0 | |||||
| Total liabilities | 1.34M | 1.01M | 1.63M | 1.97M | 3.24M | 2.72M | 2.29M | 1.74M | 2.27M | 2.54M |
| Shareholders' equity | 20.1M | 4.72M | 7.73M | 10.8M | 21.9M | 13.0M | 5.75M | 13.6M | 1.83M | 10.9M |
| Shares outstanding | 11.6M | 1.73M | 416.4K | 1.14M | 1.13M | 5.78M | 669.4K | 342.6K | 2.43M | 1.30M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -7.98M | -7.11M | -10.7M | -12.1M | -11.9M | -8.80M | -8.64M | -7.52M | -9.51M | -7.76M |
| Capital spending | -12.0K | -1.00K | -5.00K | -121.0K | -51.0K | -19.0K | -72.0K | -5.00K | -203.0K | -4.00K |
| Free cash flow | -7.99M | -7.11M | -10.8M | -12.3M | -11.9M | -8.82M | -8.72M | -7.53M | -9.72M | -7.76M |
| Cash from investing | -12.0K | 8.00K | -5.00K | -121.0K | -51.0K | -19.0K | -72.0K | -5.00K | -103.0K | 5.35M |
| Cash from financing | 23.6M | 4.00M | 7.41M | -26.0K | 21.7M | 16.1M | 772.0K | 18.8M | 292.0K | 10.2M |
| Dividends paid | -4.09M | -1.00K | ||||||||
| Share buybacks | 0 | -1.00K | -11.0K | -28 | -1 | -15.0K | 1.00K | 3.00K | 2.00K | 10.2M |
| Change in cash | 15.6M | -3.11M | -3.34M | -12.3M | 9.81M | 7.31M | -7.95M | 11.3M | -9.32M | 7.79M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 28, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 28, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Aug 14, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Aug 14, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 14, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 21, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 8-K · Current report | Apr 8, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 8, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 30, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 8-K · Current report | Feb 18, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 11, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Dec 4, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 4, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 1, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 25, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 24, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| S-3 · Registration statement | Nov 20, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| D | Nov 12, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 6, 2025 | Material contract | SEC |
| 8-K · Current report | Nov 3, 2025 | Current report | SEC |
| 8-K · Current report | Oct 31, 2025 | Management or board change | SEC |
| 4/A · Change in ownership, amended | Sep 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 15, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 11, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Aug 28, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | Aug 27, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 25, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 21, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 21, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2025 | Big-stake notice | SEC |
| D | Aug 4, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 30, 2025 | Material contract | SEC |
| ARS · Annual report to shareholders | Jul 30, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 30, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 25, 2025 | Current report | SEC |
| 8-K · Current report | Jul 7, 2025 | Current report | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Jun 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 8-K · Current report | May 7, 2025 | Current report | SEC |
| 8-K · Current report | Apr 22, 2025 | Current report | SEC |
| 8-K · Current report | Apr 9, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 3 · Initial statement of ownership | Mar 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 20, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jan 29, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 29, 2025 | Other filings | SEC |
| D | Jan 28, 2025 | Other filings | SEC |
| D | Jan 28, 2025 | Other filings | SEC |
| D | Jan 28, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 27, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 24, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 23, 2025 | Big-stake notice | SEC |
| S-1 · Registration statement | Jan 21, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 17, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 17, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 15, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 15, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 14, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 14, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| D | Jan 7, 2025 | Other filings | SEC |
| D | Jan 3, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 27, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 26, 2024 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 26, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Dec 23, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 20, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Dec 20, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 19, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 7, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Aug 9, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 5, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 2, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 1, 2024 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Jul 30, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 29, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jul 26, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 24, 2024 | Current report | SEC |
| D | Jul 23, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 12, 2024 | Material contract | SEC |
| 8-K · Current report | Jul 5, 2024 | Current report | SEC |
| 8-K · Current report | Jul 2, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 2, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 27, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 21, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 8-K · Current report | May 28, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | May 24, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 20, 2024 | Offer document | SEC |
| RW · Request to withdraw a registration | May 20, 2024 | Other filings | SEC |
| S-1 · Registration statement | May 17, 2024 | Offer document | SEC |
| 424B5 · Prospectus | May 17, 2024 | Offer document | SEC |
| 8-K · Current report | May 17, 2024 | Material contract | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | May 8, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 8, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | May 8, 2024 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 22, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 2, 2024 | Results | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 26, 2024 | Current report | SEC |
| 424B3 · Prospectus | Dec 28, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 28, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 22, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 21, 2023 | Other filings | SEC |
| S-1 · Registration statement | Dec 19, 2023 | Offer document | SEC |
| D | Dec 19, 2023 | Other filings | SEC |
| 8-K · Current report | Dec 8, 2023 | Material contract | SEC |
This page holds 200 of 900 filings. Open Filings
Cap table
Built by 6ix from Phio Pharmaceuticals Corp.’s releases · as of Nov 3, 2026
- Common shares
- 11,951,632
- Fully diluted
- 11,951,632
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 11,951,632 | Nov 3, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$2.05 · expire about Nov 2027 |
| Warrants · US$3.00 · expire about Jan 2027 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 11,951,632 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Deming Other companies: Better for You Wellness Inc. (Director · Since at least Sep 30, 2021); Sorrento Therapeutics, Inc. (Director · Jul 11, 2016 – Sep 15, 2017 · Past); Albany Molecular Research Inc (Director · Jun 15, 2016 – Aug 31, 2017 · Past) | Director · Since at least Feb 19, 2025 |
| Keith L Brownlie Other companies: Celldex Therapeutics, Inc. (Director · Since at least Jun 15, 2017); Cancer Genetics Inc (Director · Jul 24, 2013 – May 22, 2014 · Past); Soligenix, Inc. (Director · Jun 21, 2012 – Sep 27, 2018 · Past) | Director · Mar 1, 2013 – Feb 13, 2019 · Past |
| Curtis Lockshin Other companies: Xenetic Biosciences, Inc. (Chief Sciencific Officer · Dec 4, 2019 – Dec 11, 2023 · Past) | Director · Since at least Mar 1, 2021 |
| Geert Cauwenbergh | Director · Mar 1, 2013 – Feb 17, 2023 · Past |
| Greg Young | VP Corporate Services · Since at least Oct 6, 2026 |
| Jennifer Phillips | SVP of Regulatory & Corporate Affairs · Since at least Oct 19, 2026 |
| John M. Viglotti | SVP Corporate Services · Since at least Mar 10, 2026 |
| Jonathan E Freeman | Director · Since at least Sep 11, 2024 |
| Kimberly Man | Vice President of Program Development and Strategic Planning · Since at least Feb 23, 2026 |
| Lisa Carson | Chief Financial Officer · Since at least Feb 19, 2026 |
All 15 people
| Person | Seat |
|---|---|
| Pamela Pavco | Chief Development Officer · Dec 16, 2016 – Feb 1, 2017 · Past |
| Patricia A Bradford | Director · Since at least Sep 11, 2025 |
| Robert Bitterman | President & Chief Executive Officer · Since at least Sep 29, 2026 |
| Robert L Ferrara | Director · Since at least May 20, 2025 |
| R. Todd Plott | Director · Since at least Jul 21, 2026 |
Log in to ask 6ix AI your own questions about Phio Pharmaceuticals Corp.